BamSEC and AlphaSense Join Forces
Learn More

Verrica Pharmaceuticals Inc. – Credit Agreements

NASDAQ: VRCA    
Share price (6/2/26): $5.79    
Market cap (6/2/26): $99.5 million
Search in Documents
Key Exhibits
External Links

Credit Agreements Filter

EX-10.1
from 10-Q 8 pages Sixth Amendment and Waiver to Credit Agreement
12/34/56
EX-10.1
from 10-Q 9 pages Fifth Amendment and Waiver to Credit Agreement
12/34/56
EX-10.3
from 10-Q 9 pages Fifth Amendment and Waiver to Credit Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Fourth Amendment to Credit Agreement
12/34/56
EX-10.1
from 10-Q 8 pages Third Amendment and Waiver to Credit Agreement
12/34/56
EX-10.28
from 10-K 8 pages Second Amendment to Credit Agreement
12/34/56
EX-10.27
from 10-K 8 pages First Amendment to Credit Agreement
12/34/56
EX-10.1
from 10-Q 101 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Omissions Are Designated [***]. Credit Agreement Dated as of July 26, 2023 Among Verrica Pharmaceuticals Inc., as the Borrower, Orbimed Royalty & Credit Opportunities IV, LP, as the Initial Lender and Administrative Agent
12/34/56
EX-10.28
from 10-K 19 pages Loan and Securityagreement
12/34/56
EX-10.26
from 10-K 17 pages Waiver and Secondamendment to Mezzanine Loan and Securityagreement
12/34/56
EX-10.21
from 10-K 10 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed First Amendment to Loan and Security Agreement
12/34/56
EX-10.2
from 10-Q 51 pages Mezzanine Loan and Security Agreement
12/34/56
EX-10.1
from 10-Q 41 pages Loan and Security Agreement
12/34/56